Bristol-Myers Squibb has secured FDA approval for Augtyro, a lung cancer therapy it acquired as part of its $4.1 billion takeover of Turning Point Therapeutics last year t
AstraZeneca will hear back from the FDA in the first quarter of next year about its recent filing of Tagrisso in combination with chemotherapy as a first-line treatment fo
There is plenty of evidence that next-generation sequencing (NGS) for lung cancer can improve patient outcomes and save healthcare systems money, but access across Europe